- Ginsenoside Rk1
-
- $94.00 / 5mg
-
2026-04-20
- CAS:494753-69-4
- Min. Order:
- Purity: 98.46%
- Supply Ability: 10g
- Ginsenoside Rk1
-
- $0.00 / 20mg
-
2023-02-24
- CAS:494753-69-4
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
- Ginsenoside RK1
-
- $357.00 / 1KG
-
2022-02-14
- CAS:494753-69-4
- Min. Order: 1KG
- Purity: 50%
- Supply Ability: 50KG
|
| | Ginsenoside RK2 Basic information |
| Product Name: | Ginsenoside RK2 | | Synonyms: | PAN 30;3beta,12beta-Dihydroxydammar-20(21),24-diene-3-O-beta-D-glucopyranosyl(1-2)-beta-D-glucopyranoside;Ginsenoside Rk1 (Rk1:Rz1=5:2);β-D-Glucopyranoside, (3β,12β)-12-hydroxydammara-20,24-dien-3-yl 2-O-β-D-glucopyranosyl-;Ginsenoside RK2 USP/EP/BP;3β,12β-dihydroxydammar-20(21),24-diene-3-O-β-D-glucopyranosyl(1->2)-β-D-glucopyranoside;(2S,3R,4S,5S,6R)-2-(((2R,3R,4S,5S,6R)-4,5-dihydroxy-2-(((3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol;Ginsenoside Rk1 - Ginsenoside Rk1:Ginsenoside Rz1 (5:2) | | CAS: | 494753-69-4 | | MF: | C42H70O12 | | MW: | 767 | | EINECS: | | | Product Categories: | | | Mol File: | 494753-69-4.mol |  |
| | Ginsenoside RK2 Chemical Properties |
| Boiling point | 854.5±65.0 °C(Predicted) | | density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Soluble in methan | | pka | 12.85±0.70(Predicted) | | form | Powder | | color | White to light yellow | | InChIKey | KWDWBAISZWOAHD-MHOSXIPRSA-N |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | Ginsenoside RK2 Usage And Synthesis |
| Chemical Properties | White powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from ginseng. | | Uses | Ginsenoside Rk1 exhibits anticancer properties causing apoptosis in some cancer cells. |
| | Ginsenoside RK2 Preparation Products And Raw materials |
|